References
- McEvoy JP , MeyerJM, GoffDC et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80(1) , 19–32 (2005).
- Meyer JM , DavisVG, McEvoyJP et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial Phase 1. Schizophr. Res. 103(1–3) , 104–109 (2008).
- Meyer JM , DavisVG, GoffDC et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from Phase 1. Schizophr. Res. 101(1–3) , 273–286 (2008).
- Correll CU , DrussBG, LombardoI et al. Findings of a U.S. national cardiometabolic screening program among 10.084 psychiatric outpatients. Psychiatr. Serv. 61(9) , 892–898 (2010).
- Correll CU , LenczT, MalhotraAK. Antipsychotic drugs and obesity. Trends Mol. Med.17(2) , 97–107 (2011).
- Vincenzi B , BorbaCP, GrayDA et al. An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics. Ann. Clin. Psychiatry 25(2) , 141–148 (2013).
- Hennekens CH , HennekensAR, HollarD, CaseyDE. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J.150(6) , 1115–1121 (2005).
- Jellinger PS , SmithDA, MehtaAE et al. American association of clinical endocrinologists‘ guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr. Pract. 18(Suppl. 1) , S1–S78 (2012).
- Mitchell AJ , DelaffonV, VancampfortD, CorrellCU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol. Med.42(1) , 125–147 (2012).
- Morrato EH , NewcomerJW, KamatS, BaserO, HarnettJ, CuffelB. Metabolic screening after the American Diabetes Association‘s consensus statement on antipsychotic drugs and diabetes. Diabetes Care32(6) , 1037–1042 (2009).
- Morrato EH , DrussB, HartungDM et al. Metabolic testing rates in 3 state medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch. Gen. Psychiatry 67(1) , 17–24 (2010).
- Colton CW , ManderscheidRW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev. Chronic Dis.3(2) , A42 (2006).
- Ferno J , RaederMB, Vik-MoAO et al. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J. 5(5) , 298–304 (2005).
- Brown MS , GoldsteinJL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc. Natl Acad. Sci. USA96(20) , 11041–11048 (1999).
- Horton JD , GoldsteinJL, BrownMS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest.109(9) , 1125–1131 (2002).
- Gimpl G , BurgerK, FahrenholzF. A closer look at the cholesterol sensor. Trends Biochem. Sci.27(12) , 596–599 (2002).
- Le Hellard S , MuhleisenTW, DjurovicS et al. Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcription factors controlling cellular lipogenesis, are associated with schizophrenia in German and Scandinavian samples. Mol. Psychiatry 15(5) , 463–472 (2010).
- Kristiana I , SharpeLJ, CattsVS, Lutze-MannLH, BrownAJ. Antipsychotic drugs upregulate lipogenic gene expression by disrupting intracellular trafficking of lipoprotein-derived cholesterol. Pharmacogenomics J.10(5) , 396–407 (2010).
- Raeder MB , FernoJ, Vik-MoAO, SteenVM. SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects? Mol. Cell. Biochem.289(1–2) , 167–173 (2006).
- Bartzokis G . Neuroglialpharmacology: white matter pathophysiologies and psychiatric treatments. Front. Biosci.16 , 2695–2733 (2011).
- Takahashi N , SakuraiT, DavisKL, BuxbaumJD. Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Prog. Neurobiol.93(1) , 13–24 (2011).
- Saher G , BruggerB, Lappe-SiefkeC et al. High cholesterol level is essential for myelin membrane growth. Nat. Neurosci. 8(4) , 468–475 (2005).
- Spitzer RL , WilliamsJB, GibbonM, FirstMB. The structured clinical interview for DSM-III-R (SCID). I: History, rationale, and description. Arch. Gen. Psychiatry49(8) , 624–629 (1992).
- Lahiri DK , NurnbergerJI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res.19(19) , 5444 (1991).
- Salek L , LutucutaS, BallantyneCM, GottoAM Jr, Marian AJ. Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. J. Mol. Med. (Berl.).80(11) , 737–744 (2002).
- Fiegenbaum M , SilveiraFR, van der Sand CR et al. Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes. Pharmacogenomics J.5(6) , 359–364 (2005).
- Rudolph MC , MonksJ, BurnsV et al. Sterol regulatory element binding protein and dietary lipid regulation of fatty acid synthesis in the mammary epithelium. Am. J. Physiol. Endocrinol. Metab. 299(6) , E918–E927 (2010).